Shares of Natera Inc. (NTRA) ticked up a bit in premarket trading after a Delaware court handed the company a nice win in a patent battle. The court said Natera gets a 30% ongoing royalty on revenues that come in after an injunction, all tied to its MRD-related patents. That's on top of a jury award from earlier that gave them a 20.5% royalty on sales before the injunction, which stays as is. The court also backed up the findings that the patents are valid and were infringed by ArcherDx and Invitae.

Natera says this decision shows its MRD patent portfolio is strong, which is part of a bigger pile of more than 650 patents it has either issued or pending. So, if you're keeping score, they've now got royalties locked in for both past and future sales in this fight.

Technical Analysis

At $212.00, the stock is trading 7.1% above its 20-day simple moving average of $198.02, which hints at a positive short-term trend. But it's also 4.0% below its 100-day SMA of $219.58, pointing to some intermediate-term weakness that traders might want to watch. The relative strength index is at 56.03, suggesting neutral momentum, while the MACD shows bullish sentiment with the MACD line at 0.0940 above the signal line of -2.5301. Put it together, and the stock isn't overbought, but there's room for it to move up.

• Key Resistance: $220.00 — where selling pressure could pop up.
• Key Support: $200.00 — a spot where buyers might step in.

Over the past 12 months, the stock has jumped 38.73%, showing strong investor interest. Right now, it's hanging out near the middle of its 52-week range, which suggests a balanced position in its historical trading.

Earnings & Analyst Outlook

Natera is set to give its next financial update on May 7, 2026 (that's an estimate). Here's what the numbers look like:

• EPS Estimate: Loss of 56 cents (up from a loss of 50 cents year-over-year).
• Revenue Estimate: $616.65 million (up from $501.83 million year-over-year).

Analysts are generally bullish, with a Buy rating and an average price target of $248.06. Recent moves include:

• Morgan Stanley: Overweight (lowered target to $250.00 on March 3).
• Wells Fargo: Equal-Weight (raised target to $215.00 on Feb. 27).
• Evercore ISI Group: Outperform (raised target to $260.00 on Feb. 27).

MarketDash Edge Rankings

Looking at market data for Natera, it shows strengths compared to the broader market:

• Momentum: Strong (Score: 66.45) — the stock is outperforming the market.

The takeaway: Natera's signal reveals a momentum-driven story, meaning it's in a favorable spot relative to market trends right now.

Top ETF Exposure

Natera pops up in a few key ETFs, which matters because big moves in these funds can push the stock around:

• ARK Genomic Revolution ETF (ARKG): 4.10% weight.
• VanEck Biotech ETF (BBH): 4.28% weight.
• Invesco Dorsey Wright Healthcare Momentum ETF (PTH): 3.09% weight.

Why this is a big deal: Since NTRA has a decent chunk of these ETFs, any significant money flowing in or out of them could force automatic buying or selling of the stock, adding an extra layer of volatility.

Price Action

Natera shares were up 0.55% at $212.00 during premarket trading on Thursday, according to market data.